TNF抗体—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human colorectal cancer tissue using P06788(TNF Antibody) at dilution 1/25. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P06788(TNF Antibody) at dilution 1/25. (Original magnification: ×200)    

  
  

Tumor Necrosis Factor (TNF) is a pro-inflammatory cytokine primarily produced by macrophages and lymphocytes, playing a central role in regulating immune responses, inflammation, and apoptosis. Discovered in the 1970s for its ability to induce tumor cell death, TNF is now recognized as a key mediator in autoimmune and chronic inflammatory diseases, such as rheumatoid arthritis, inflammatory bowel disease (IBD), and psoriasis. Dysregulated TNF signaling can lead to excessive inflammation, tissue damage, and disease progression.

TNF antibodies are biologic therapies designed to neutralize TNF activity. The first anti-TNF agents, developed in the 1990s, revolutionized treatment paradigms. These monoclonal antibodies (e.g., infliximab, adalimumab) or soluble TNF receptor fusion proteins (e.g., etanercept) bind TNF-α, preventing its interaction with cell surface receptors. This inhibition reduces inflammatory cascades, alleviates symptoms, and slows joint or tissue damage in autoimmune conditions.

Despite their efficacy, TNF blockers carry risks, including increased susceptibility to infections (e.g., tuberculosis reactivation) and potential drug-induced lupus. Ongoing research focuses on optimizing dosing, developing biosimilars, and exploring next-generation inhibitors with improved safety profiles. TNF antibodies remain a cornerstone in managing refractory autoimmune diseases, highlighting the importance of balancing therapeutic benefits with adverse effects.